Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 2
2012 1
2014 3
2016 1
2017 1
2018 3
2019 1
2020 5
2021 4
2022 6
2023 4
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Short-Term Effectiveness and Safety of Biologics and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review and Network Meta-Analysis.
Pereyra-Rodriguez JJ, Alcantara-Luna S, Domínguez-Cruz J, Galán-Gutiérrez M, Ruiz-Villaverde R, Vilar-Palomo S, Armario-Hita JC. Pereyra-Rodriguez JJ, et al. Among authors: armario hita jc. Life (Basel). 2021 Sep 6;11(9):927. doi: 10.3390/life11090927. Life (Basel). 2021. PMID: 34575076 Free PMC article. Review.
Upadacitinib for moderate to severe atopic dermatitis.
Navarro-Triviño F, Alcantara-Luna S, Domínguez-Cruz J, Galán-Gutiérrez M, Ruiz-Villaverde R, Pereyra-Rodriguez JJ, Armario-Hita JC. Navarro-Triviño F, et al. Among authors: armario hita jc. Immunotherapy. 2023 Aug;15(11):799-808. doi: 10.2217/imt-2023-0037. Epub 2023 May 17. Immunotherapy. 2023. PMID: 37194577 Review.
Omalizumab: what benefits should we expect?
Giménez-Arnau A, Velasco M, Armario Hita JC, Labrador-Horrillo M, Silvestre Salvador JF. Giménez-Arnau A, et al. Among authors: armario hita jc. Eur J Dermatol. 2016 Aug 1;26(4):340-4. doi: 10.1684/ejd.2016.2809. Eur J Dermatol. 2016. PMID: 27210073 Free article.
Optimising the Therapeutic Interval for Biologics in Patients with Psoriasis.
Dodero-Anillo JM, Lozano-Cuadra IC, Rios-Sanchez E, Pedrosa-Martinez MJ, Ruiz-Carrascosa JC, Galan-Gutierrez M, Armario-Hita JC. Dodero-Anillo JM, et al. Among authors: armario hita jc. Life (Basel). 2022 Dec 10;12(12):2075. doi: 10.3390/life12122075. Life (Basel). 2022. PMID: 36556440 Free PMC article.
Long-Term Effectiveness and Safety of Biologic and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review.
Ayen-Rodríguez A, Pereyra-Rodríguez JJ, Navarro-Triviño FJ, Alcantara-Luna S, Domínguez-Cruz J, Galán-Gutiérrez M, Vilar-Palomo S, Armario-Hita JC, Ruiz-Villaverde R. Ayen-Rodríguez A, et al. Among authors: armario hita jc. Life (Basel). 2022 Jul 30;12(8):1159. doi: 10.3390/life12081159. Life (Basel). 2022. PMID: 36013338 Free PMC article. Review.
Response to "Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis'".
Rand K, Ramos-Goñi JM, Akmaz B, Solé-Feu L, Armario-Hita JC. Rand K, et al. Among authors: armario hita jc. Dermatol Ther (Heidelb). 2024 Mar;14(3):823-827. doi: 10.1007/s13555-024-01107-1. Epub 2024 Mar 5. Dermatol Ther (Heidelb). 2024. PMID: 38438784 Free PMC article. No abstract available.
34 results